Lightbits Labs Closes Q1-2025 with Record-Breaking Growth
Lightbits Labs (Lightbits®), the inventor of the NVMe® over TCP protocol offering next-gen software-defined storage for modern workloads, today announced record-breaking growth for Q1’25. This milestone reflects strong global demand for infrastructure modernization that models Cloud Operations enabled by high-performance block storage offering flexibility, reliability, and cost-efficiency at scale.
The breakout quarter for Lightbits, marked by a 4.8X increase in software sales and a 2.9X increase in average deal size, is fueled by a surge in new customers and strong customer loyalty, as evidenced by an impressive 2X YoY license increase. New account growth was particularly strong among financial services, service providers, and e-commerce organizations who require high-performance, low-latency at massive scale.
A strong standout use case for Lightbits was among AI Cloud service providers. Crusoe expanded its use of Lightbits to power high-performance, multi-petabyte-scale AI cloud services. Elastx implemented Lightbits to support secure, scalable, and sustainable OpenStack, Kubernetes, and AI cloud services. And cloud company Nebul uses Lightbits to underpin its high-performance, cost-efficient data platform for enterprise AI deployments.
"The quarter close marked significant progress financially and strategically,” said Eran Kirzner, CEO and co-founder of Lightbits Labs. “Our growth is a direct result of the trust and value customers place in Lightbits’ solutions, delivering unmatched performance and efficiency for modern applications in containerized and virtualized environments at scale. We now service Fortune 500 financial institutions, as well as some of the world’s largest e-Commerce platforms and AI cloud companies.”
Lightbits offers best-in-class software-defined storage that redefines performance and efficiency for open source environments like Kubernetes, KVM, OpenShift, and OpenStack, delivering the industry’s best price/performance for AI/ML, analytics, and transactional workloads at scale. The storage software scales to hundreds of petabytes and delivers performance of up to 75 million IOPS and consistent sub-millisecond tail latency under a heavy load. The unique NVMe over TCP architecture utilizes resources more efficiently with less proprietary hardware, simplifying storage management and requiring 5X less hardware compared to Ceph Storage, which reduces energy consumption and satisfies sustainability strategies. To support mixed workload environments, a single Lightbits cluster provides multi-tenancy with Quality of Service capabilities to prevent resource hogging.
“Legacy storage infrastructure can and will impact application performance of data-driven environments. Thus, storage is fundamental and must be the first consideration of any modernization effort,” said Matt Kimball, Vice President & Principal Analyst at Moor Insights & Strategy. “As more organizations shift to AI and real-time data workloads, the importance of flexible, disaggregated storage solutions becomes critical. Scale matters, and performant scale is even more important. Companies like Lightbits Labs deliver performance, scale, and cost savings realized by some of the largest organizations.”
Lightbits Labs' success is further amplified by its growing global partner network, highlighted by several announcements last year:
- Lightbits Labs joined the Mirantis Partner Program, providing scalable and resilient high-performance storage for Kubernetes
- Lightbits Certified on Oracle Cloud Infrastructure
“We're seeing a consistent pattern of engagement with customers finding that other software-defined storage can only accommodate low and middle-tier workloads. They adopt Lightbits for tier 1 workloads, and then we move downstream to their utility tier, as well. And customers seeking VMware alternatives like Lightbits for its seamless integrations with OpenShift and Kubernetes to enable their infrastructure modernization,” added Rex Manseau, Chief Revenue Officer of Lightbits Labs. “The unmatched capabilities of Lightbits, combined with the compatibility with common orchestration environments, make it an ideal choice for organizations and service providers who are supporting diverse performance-sensitive workloads at scale to capitalize on rapidly expanding business opportunities.”
Recently, the company’s solutions and commitment to excellence were given industry recognition through many prestigious awards, including:
- CRN’s Storage 100
- CRN's 50 Coolest Software-Defined Storage Vendors
- Data Breakthrough Award
- SDC and Cloud Award
Lightbits also received analyst recognition from GigaOM, positioned as a Fast-Moving Leader for Primary Storage in their 2024 Primary Storage Report, further cementing its reputation in the market.
Looking ahead, Lightbits Labs is poised to expand its global install base, prioritizing key markets across the Americas and Europe, and other high-growth regions. With more new products and partnership announcements in the pipeline for later this year, the company continues to innovate and expand its footprint in the storage market and intensify its focus on delivering cutting-edge solutions for broader workload coverage.
In 2025, you can connect with Lightbits software-defined storage experts at these industry events: The Red Hat Summit, StackConf, and KubeCon.
Visit our website to learn more about why leading organizations choose Lightbits software-defined storage or book a product demonstration today.
About Lightbits Labs
Lightbits Labs® (Lightbits) invented the NVMe over TCP protocol and offers best-in-class software-defined block storage that enables data center infrastructure modernization for organizations building a private or public cloud. Built from the ground up for low consistent latency, scalability, resiliency, and cost-efficiency, Lightbits software delivers the best price/performance for real-time analytics, transactional, and AI/ML workloads. Lightbits Labs is backed by enterprise technology leaders [Cisco Investments, Dell Technologies Capital, Intel Capital, Lenovo, and Micron] and is on a mission to deliver the fastest and most cost-efficient data storage for performance-sensitive workloads at scale.
To learn more about Lightbits Labs, visit https://www.lightbitslabs.com/ and follow Lightbits Labs on Linkedin, X, Facebook, Instagram, and YouTube.
Lightbits and Lightbits Labs are registered trademarks of Lightbits Labs, Ltd.
All trademarks and copyrights are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250415197129/en/
Contacts
Lightbits PR Contact:
Carol Platz
pr@lightbitslabs.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press Release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press Release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
Incyte to Highlight Early-Stage Oncology Data at American Association for Cancer Research Annual Meeting 202525.4.2025 14:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced that the Company will present new early-stage data from its oncology portfolio at the American Association of Cancer Research (AACR) Annual Meeting 2025 in Chicago, IL, from April 25–30. “At AACR we will be presenting data from early-stage programs across our oncology portfolio, including for patients with myeloproliferative neoplasms, ovarian cancer and other solid tumors,” said Pablo J. Cagnoni, M.D., President and Head of Research and Development, Incyte. “These data will guide our approach as we advance our pipeline and seek to transform the treatment landscape for patients with cancer and myeloproliferative neoplasms.” Abstracts accepted for presentation at AACR include: Mini Symposium INCB177054 INCB177054: A Novel, Potent, Orally Bioavailable DGKα/ζ Dual Inhibitor Enhances T-Cell Function and Demonstrates Potent Antitumor Activity (Session Title: Novel Antitumor Agents. April 28, 4:50 p.m. – 5:05 p.m. ET (3:50 p.m. – 4:05 p.m. CT). Abstract #
SLB Announces First-Quarter 2025 Results; Remains Committed to Return a Minimum of $4 Billion to Shareholders in 202525.4.2025 12:50:00 CEST | Press Release
SLB (NYSE: SLB) today announced results for the first-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423635499/en/ The exterior of the SLB headquarters in Houston, Texas. First-Quarter Results (Stated in millions, except per share amounts) Three Months EndedChange Mar. 31, 2025 Dec. 31, 2024 Mar. 31, 2024 Sequential Year-on-year Revenue $8,490 $9,284 $8,707 -9% -3% Income before taxes - GAAP basis $1,063 $1,387 $1,357 -23% -22% Income before taxes margin - GAAP basis 12.5% 14.9% 15.6% -241 bps -306 bps Net income attributable to SLB - GAAP basis $797 $1,095 $1,068 -27% -25% Diluted EPS - GAAP basis $0.58 $0.77 $0.74 -25% -22% Adjusted EBITDA* $2,020 $2,382 $2,057 -15% -2% Adjusted EBITDA margin* 23.8% 25.7% 23.6% -186 bps 18 bps Pretax segment operating income* $1,556 $1,918 $1,649 -19% -6% Pretax segment operating margin* 18.3% 20.7% 18.9% -232 bps -60 bps Net income attributable to SLB, excluding charges &
Corona, The World’s Most Valuable Beer Brand 1 , Announces Its 100-Year Anniversary with Global Celebration25.4.2025 10:00:00 CEST | Press Release
Today, Corona proudly celebrates its 100-year anniversary, a remarkable milestone for the iconic brand that has been synonymous with the beach and enjoyed by consumers worldwide for the past century. Since 1925, Corona has cultivated a deep association with the beach; fully embodying a lifestyle connected to nature and relaxation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425804516/en/ Corona 100 This Is Living Since 1925 In honor of the occasion, Corona invites everyone to live their “beach side” – a.k.a. their best side – at top-tier beach locations across the globe. The Corona 100 platform includes a film highlighting 100 years of beach culture, a definitive list of the top 100 beaches in the world to visit, and a signed multi-year sponsorship of a renowned concert at Copacabana Beach in Rio de Janeiro — all offering people across the globe opportunities to connect with their beach side. “For 100 years, Corona has
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom